Showing results (51-60 of 210) with videos related to
Sort By:
Pageof 21
Accident; Analysis and Prevention|October 5, 2020
Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 SurveyThomas R Arkell, Nicholas Lintzeris, Llewellyn Mills, et al.Harm Reduction Journal|July 30, 2022
Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)Nicholas Lintzeris, Llewellyn Mills, Sarah V Abelev, et al.Epilepsia Open|February 22, 2023
Ictal vocalizations in the Scn1a<sup>+/-</sup> mouse model of Dravet syndromeLyndsey L Anderson, Declan Everett-Morgan, Stela P Petkova, et al.Biochemical Society Transactions|October 31, 2015
Understanding the function of ABCA7 in Alzheimer's diseaseHongyun Li, Tim Karl, Brett GarnerBehavioural Pharmacology|July 30, 2016
The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's diseaseTim Karl, Brett Garner, David ChengBehavioural Brain Research|August 28, 2023
Light phase does not affect operant sucrose self-administration in adult male C57BL/6JAbr miceGeorgia Watt, Tim Karl, Rose ChesworthBioscience Reports|January 22, 2016
Abca7 deletion does not affect adult neurogenesis in the mouseHongyun Li, Tim Karl, Brett GarnerMolecular Neurobiology|November 17, 2025
Cannabidiol Modulates Brain Copper Homeostasis in Wild-Type-Like But Not Alzheimer's Disease Transgenic Female Mice: Implications for Neuroprotective TherapyAnthony Dosseto, Kaila Tonge, Tim KarlThe European Journal of Neuroscience|July 12, 2008
Behavioural profile of a new mouse model for NPY deficiencyTim Karl, Liesl Duffy, Herbert HerzogProgress in Neuro-Psychopharmacology & Biological Psychiatry|March 8, 2025
Persistent behavioural consequences of chronic adolescent cannabidiol (CBD) in a mouse model with increased susceptibility to Δ<sup>9</sup>-tetrahydrocannabinol and schizophreniaGabriela Visini, Rose Chesworth, Tim KarlPageof 21